Bokf, Na Argenx Se Transaction History

Bokf, Na

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$356.01 - $451.55 $1,780 - $2,257	5 Added 0.74%	677 $291,000
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $5,711 - $6,612	-16 Reduced 2.33%	672 $264,000
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $3,389 - $5,060	10 Added 1.47%	688 $261,000
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $7,017 - $10,420	19 Added 2.88%	678 $333,000
Q2 2023 Aug 21, 2023	SELL	$360.14 - $422.58 $3,241 - $3,803	-9 Reduced 1.35%	659 $256,000
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $223,265 - $269,638	668 New	668 $248,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

Stay updated on Bokf, Na with notifications on news.